Evidence map›Paper›PMID 26582052›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2015

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.

Nick Freemantle, Muhammad Mamdani, Tina Vilsbøll, Jens Harald Kongsø, Kajsa Kvist, Stephen C Bain

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01617434. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01617434 phase3completed

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Ran2012Enrolled451Registered outcomes9Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo
PMID 26179619other papers from this trial
Open the trial in the graph
NCT00972283 phase3completednot on this map

NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)

TypeinterventionalSponsorNovo Nordisk A/SRan2009 to 2010Enrolled1,006ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec, insulin glargine, insulin aspart
NCT01045447 phase3completednot on this map

A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL)

TypeinterventionalSponsorNovo Nordisk A/SRan2010 to 2010Enrolled465ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec/insulin aspart, insulin glargine
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2019
    Guideline
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Nick FreemantleDepartment of Primary Care and Population Health, UCL Medical School, London, UK. nicholas.freemantle@ucl.ac.uk.
Muhammad MamdaniDepartment of Health Policy, Management and Evaluation (Faculty of Medicine), University of Toronto, Ontario, Canada.
Tina VilsbøllCenter for Diabetes Research, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
Jens Harald KongsøNovo Nordisk A/S, Søborg, Denmark.
Kajsa KvistNovo Nordisk A/S, Bagsvaerd, Denmark.
Stephen C BainDiabetes and Endocrinology, Institute of Life Science, Swansea University, Swansea, UK.
Novo Nordisk (Denmark) · DKSwansea University · GBUniversity College London · GBUniversity of Copenhagen · DKUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIDegLira is a once-daily combination of insulin degludec (IDeg) and liraglutide. Trials directly comparing IDegLira with alternative strategies for intensifying basal insulin are ongoing. While awaiting results, this analysis compared indirectly how different strategies affected glycated hemoglobin (HbA

methodsA pooled analysis of five completed Novo Nordisk randomized clinical trials in patients with type 2 diabetes inadequately controlled on basal insulin was used to compare indirectly IDegLira (N = 199) with: addition of liraglutide to basal insulin (N = 225) [glucagon-like peptide-1 receptor agonist (GLP-1RA) add-on strategy]; basal-bolus (BB) insulin [insulin glargine (IGlar) + insulin aspart] (N = 56); or up-titration of IGlar (N = 329). A supplementary analysis was performed with the BB arm including patients who received IGlar or IDeg as basal insulin in the relevant trial (N = 210). All trials had comparable inclusion/exclusion criteria and baseline characteristics. Individual patient-level data were analyzed using multivariable statistical models with potential baseline heterogeneity accounted for using explanatory variables.

resultsAt end of study, differences between IDegLira and BB or up-titrated IGlar, respectively, were as follows: reduction in HbA

conclusionThese results suggest that IDegLira may be more effective, with lower hypoglycemia rates and less weight gain, than up-titrated basal insulin or BB in patients uncontrolled on basal insulin.

Indexed as

Basal insulinIDegLiraInsulin degludecIntensificationLiraglutideType 2 diabetes

Identifiers

PMID26582052
PMCPMC4674480
OpenAlexW2172438155

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.